(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 13.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Aurinia Pharmaceuticals's revenue in 2026 is $311,507,000.On average, 9 Wall Street analysts forecast AUPH's revenue for 2026 to be $44,820,946,964, with the lowest AUPH revenue forecast at $42,324,907,052, and the highest AUPH revenue forecast at $47,010,969,189. On average, 9 Wall Street analysts forecast AUPH's revenue for 2027 to be $52,706,889,692, with the lowest AUPH revenue forecast at $46,940,452,070, and the highest AUPH revenue forecast at $64,124,010,418.
In 2028, AUPH is forecast to generate $60,689,959,772 in revenue, with the lowest revenue forecast at $51,504,107,133 and the highest revenue forecast at $78,807,537,318.